Crescent Biopharma
CBIO
29 hedge funds and large institutions have $79.3M invested in Crescent Biopharma in 2015 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 14 increasing their positions, 4 reducing their positions, and 3 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 4
2% more capital invested
Capital invested by funds: $77.4M → $79.3M (+$1.92M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 31 → 29 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$992K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$262K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$166K |
| 4 |
Renaissance Technologies
New York
|
+$86.8K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$68.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.16M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$196K |
| 3 |
SIM
Spark Investment Management
New York
|
-$56.3K |
| 4 |
Morgan Stanley
New York
|
-$33.1K |
| 5 |
Citigroup
New York
|
-$11K |
CBIO Hedge Fund Activity: Q4 2015 in Review
29 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q4 2015, worth a combined $79.3M — up 2.5% from $77.4M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CBIO and 1 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 14 added.
The largest buyer was Franklin Resources, adding an estimated $992K. The largest seller was Cormorant Asset Management, cutting an estimated $1.16M.
- 29 institutional investors held Crescent Biopharma (CBIO) as of Q4 2015, down from 31 in Q3 2015.
- Funds reported $79.3M of Crescent Biopharma stock for Q4 2015, up 2.5% quarter-over-quarter.
- 1 fund opened new Crescent Biopharma positions in Q4 2015 and 3 closed out, a net change of -2 holders.
- The largest Crescent Biopharma buyer in Q4 2015 was Franklin Resources, an estimated $992K added.
- The largest Crescent Biopharma seller in Q4 2015 was Cormorant Asset Management, an estimated $1.16M sold.
Based on aggregated 13F filings for Q4 2015.